FrancophonIA/ELRC3.0 huggingface dataset:
English: <7 mg Fe/g dw or ≤2,000 µg/l
Danish: <7 mg Fe/g tørvægt eller ≤2.000 µg/l
English: Serum ferritin assessed by monthly monitoring reflected changes in liver iron concentration indicating that trends in serum ferritin can be used to monitor response to therapy.
Danish: Serum-ferritin, der blev vurderet ved månedlig monitorering, afspejlede ændringer i lever-jernkoncentration.
English: It appeared from a post-hoc analysis of this study that, in the subgroup of patients with liver iron concentration ≥7 mg Fe/g dw treated with deferasirox dispersible tablets (20 and 30 mg/kg) or deferoxamine (35 to ≥50 mg/kg), the non-inferiority criteria were achieved.
Danish: I en post-hoc-analyse af dette studie blev non-inferiority-kriteriet opnået i undergruppen af patienter med leverjernkoncentration ≥ 7 mg Fe/g biopsi-tørvægt behandlet med deferasirox dispergible tabletter (20 og 30 mg/kg) eller deferoxamin (35 til ≥ 50 mg/kg).
English: • EXJADE 360 mg film-coated tablets are dark blue and stamped “360” on one side and “NVR”
Danish: • EXJADE 360 mg filmovertrukne tabletter er mørkeblå og præget med ”360” på den ene side og
English: Once a satisfactory body iron level has been achieved (LIC <3 mg Fe/g dw or serum ferritin <300 µg/l), treatment should be stopped.
Danish: Behandlingen skal ophøre, når der er opnået et tilfredsestillende jernniveau i kroppen (LIC < 3 mg Fe/g tørvægt eller serumferritin < 300 µg/l).
English: A food-effect study involving administration of the film-coated tablets to healthy volunteers under fasting conditions and with a low-fat (fat content <10% of calories) or high-fat (fat content >50% of calories) meal indicated that the AUC and Cmax were slightly decreased after a low-fat meal (by 11% and 16%, respectively).
Danish: Et studie om madens effekt på indtagelse af filmovertrukne tabletter hos raske, fastende forsøgspersoner sammen med et måltid med enten et lavt fedtindhold (fedtindhold<10% af kalorieindtaget) eller sammen med et måltid med et højt fedtindhold (fedtindhold>50% af kalorieindtaget), viste et lille fald i AUC og Cmax (11% og 16%, respektivt).
English: Starting dose 14 mg/kg/day 20 mg/kg/day After 20 units (about 100 ml/kg) of PRBC
Danish: 14 mg/kg/day 20 mg/kg/dag Efter 20 enheder (ca. 100 ml/kg) af
English: (acquired Fanconi syndrome), glycosuria
Danish: (erhvervet Fanconis syndrom),
English: EXJADE 125 mg dispersible tablets EXJADE 250 mg dispersible tablets EXJADE 500 mg dispersible tablets
Danish: EXJADE 125 mg dispergible tabletter EXJADE 250 mg dispergible tabletter EXJADE 500 mg dispergible tabletter
English: Multipack: 300 (10 packs of 30) film-coated tablets
Danish: Multipakning: 300 (10 pakker á 30) filmovertrukne tabletter
English: EXJADE dispersible tablets must therefore be taken on an empty stomach at least 30 minutes before food, preferably at the same time each day (see sections 4.2 and 5.2).
Danish: EXJADE dispergible tabletter skal derfor tages på tom mave, mindst 30 minutter før et måltid og helst på samme tidspunkt hver dag (se punkterne 4.2 og 5.2).
English: Once the cause of the liver function test abnormalities has been clarified or after return to normal levels, cautious re-initiation of treatment at a lower dose followed by gradual dose escalation may be considered.
Danish: En forsigtig genstart af behandling med lavere dosis, efterfulgt af en gradvis dosisforøgelse kan overvejes, når årsagen til leverfunktionstest-uregelmæssigheder er blevet klarlagt, eller når der igen er normale niveauer.
English: • EXJADE 125 mg tablets are stamped “J 125” on one side and “NVR” on the other.
Danish: • EXJADE 125 mg tabletter er præget med ”J 125” på den ene side og ”NVR” på den anden side.
English: A food-effect study involving administration of the granules to healthy volunteers under fasting conditions and with a low-fat (fat content = approximately 30% of calories) or high-fat (fat content >50% of calories) meal indicated that the AUC and Cmax were slightly decreased after a low-fat meal (by 10% and 11%, respectively).
Danish: Et studie om madens effekt på indtagelse af granulat hos raske, fastende forsøgspersoner sammen med et måltid med enten et lavt fedtindhold (fedtindhold = ca. 30% af kalorieindtaget) eller sammen med et måltid med et højt fedtindhold (fedtindhold>50% af kalorieindtaget), viste et lille fald i AUC og Cmax (10% og 11%, respektivt).
English: EXJADE 125 mg, 250 mg and 500 mg dispersible tablets are available in unit packs containing 28, 84 or 252 dispersible tablets.
Danish: EXJADE 125 mg, 250 mg og 500 mg dispergible tabletter er tilgængelig i enkeltpakninger med 28, 84 eller 252 dispergible tabletter.
English: If you are switching from the film-coated tablets or granules to these dispersible tablets, you will need an adjustment of the dose.
Danish: Hvis du skal skifte fra filmovertrukne tabletter eller granulat til disse dispergible tabletter, skal din dosis justeres.
English: EXJADE granules should be taken by sprinkling the full dose onto soft food such as yogurt or apple sauce (pureed apple).
Danish: EXJADE granulat bør indtages ved at drysse hele dosis over blød mad, som fx yoghurt eller æblemos.
English: EXJADE film-coated tablets may be taken either on an empty stomach or with a light meal, preferably at the same time each day (see sections 4.2 and 5.2).
Danish: EXJADE filmovertukne tabletter kan tages på tom mave eller med et let måltid og helst på samme tidspunkt hver dag (se punkterne 4.2 og 5.2).
English: If you are switching from the dispersible tablets to these granules, you will need an adjustment of the dose.
Danish: Hvis du skal skifte fra dispergible tabletter til dette granulat, skal din dosis justeres.
English: Stevens-Johnson syndrome
Danish: Stevens-Johnsons syndrom 1, allergisk vaskulitis
English: - if you notice a marked decrease in your urine output (sign of kidney problem).
Danish: - hvis du opdager en markant nedsættelse af din urinmængde (tegn på nyresygdom).
English: Dispersible tablets
Danish: Dispergible tabletter
English: Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported with the use of EXJADE (see section 4.4).
Danish: Der er rapporteret alvorlige kutane bivirkninger (SCAR), herunder Stevens-Johnsons syndrom (SJS), toksisk epidermal nekrolyse (TEN) og lægemiddelreaktioner med eosinofili og systemiske symptomer (DRESS) ved brug af EXJADE (se pkt.
English: If no satisfactory control is achieved at doses above 21 mg/kg, treatment at such doses should not be maintained and alternative treatment options should be considered whenever possible.
Danish: Hvis der ikke opnås tilfredsstillende kontrol ved doser over 21 mg/kg, bør behandlingen ikke opretholdes, og når det er muligt, bør alternativ behandling overvejes.
English: In a healthy volunteer study, the concomitant administration of deferasirox as a CYP1A2 inhibitor (repeated dose of 30 mg/kg/day, dispersible tablet formulation) and the CYP1A2 substrate theophylline (single dose of 120 mg) resulted in an increase of theophylline AUC by 84% (90% CI: 73% to 95%).
Danish: I et studie med raske frivillige blev det påvist, at samtidig administration af deferasirox som CYP1A2hæmmer (gentagen dosis på 30 mg/kg daglig, dispergibel tablet-formulering) og CYP1A2-substratet theophyllin (enkeltdosis på 120 mg) øgede theophyllin-AUC med 84% (90% CI: 73% til 95%).
English: On average, serum ferritin decreased by 222.0 µg/l in patients treated with deferasirox dispersible tablets (starting dose 10 mg/kg/day) and increased by 115 µg/l in patients treated with placebo (p<0.001).
Danish: I gennemsnit faldt serumferritin med 222,0 µg/l hos patienter, der blev behandlet med deferasirox dispergible tabletter (startdosis 10 mg/kg/dag), og steg med 115 µg/l hos patienter, der fik placebo (p<0,001).
English: If no satisfactory control is achieved at doses above 30 mg/kg, treatment at such doses should not be maintained and alternative treatment options should be considered whenever possible.
Danish: Hvis der ikke opnås tilfredsstillende kontrol ved doser over 30 mg/kg, bør behandlingen ikke opretholdes, og når det er muligt, bør alternativ behandling overvejes.
English: In patients treated with doses >30 mg/kg/day - When target is reached
Danish: Til patienter behandlet med doser >30 mg/kg/day
English: • EXJADE 500 mg tablets are stamped “J 500” on one side and “NVR” on the other.
Danish: • EXJADE 500 mg tabletter er præget med ”J 500” på den ene side og ”NVR” på den anden side.
English: • EXJADE 250 mg tablets are stamped “J 250” on one side and “NVR” on the other.
Danish: • EXJADE 250 mg tabletter er præget med ”J 250” på den ene side og ”NVR” på den anden side.
English: If serum ferritin falls consistently below 500 µg/l (in transfusional iron overload) or below 300 µg/l (in non-transfusion-dependent thalassaemia syndromes), an interruption of treatment should be considered.
Danish: Det skal overvejes at afbryde behandlingen, hvis serum-ferritin falder konsekvent under 500 µg/l (ved transfusionsbetinget jernophobning) eller under 300 µg/l (ved ikke-transfusionsafhængige talassæmi-syndromer).
English: >14 ml/kg/month of PRBC (approx. >4 units/month for an adult)
Danish: >14 ml/kg/måned af PRBC (ca. >4 enheder/måne d for en voksen)
English: - If you have any further questions, ask your doctor or pharmacist.
Danish: Er du i tvivl, så spørg lægen eller apoteketspersonalet.
English: For patients in whom the dose was increased to >10 mg/kg, dose reduction to 10 mg/kg or less is recommended when LIC is <7 mg Fe/g dw or serum ferritin is ≤2,000 µg/l.
Danish: Hos patienter, hvor dosis er øget til > 10 mg/kg, anbefales det at reducere dosis til 10 mg/kg eller derunder, når LIC er < 7 mg Fe/g tørvægt eller serumferritin er ≤ 2000 µg/l.
English: In patients whose serum ferritin level has reached the target (usually between 500 and 1,000 µg/l), dose reductions in steps of 5 to 10 mg/kg should be considered to maintain serum ferritin levels within the target range and to minimise the risk of overchelation.
Danish: Hos patienter, hvis serum-ferritinniveauer har nået målet (som regel mellem 500 og 1.000 µg/l), bør det overvejes at foretage dosisreduktion i trin på 5 til 10 mg/kg for at vedligeholde serum-ferritinniveauer inden for det terapeutiske interval, og for at minimere risikoen for overkelering.
English: However, in patients with liver iron concentration <7 mg Fe/g dw treated with deferasirox dispersible tablets (5 and 10 mg/kg) or deferoxamine (20 to 35 mg/kg), non-inferiority was not established due to imbalance in the dosing of the two chelators.
Danish: Hos patienter med lever-jernkoncentration < 7 mg Fe/g biopsi-tørvægt, der blev behandlet med deferasirox dispergible tabletter (5 og 10 mg/kg) eller deferoxamin (20 eller 35 mg/kg), blev non-inferiority imidlertid ikke opnået.
English: A higher or lower starting dose may be recommended by your doctor based on your individual treatment needs.
Danish: Det kan være, at lægenafhængigt af dit behov - anbefaler en højere eller lavere startdosis.
English: Approximate tablet dimensions 17 mm x 6.7 mm.
Danish: Omtrentlige tabletdimensioner 17 mm x 6,7 mm.
English: Approximate tablet dimensions 14 mm x 5.5 mm.
Danish: Omtrentlige tabletdimensioner 14 mm x 5,5 mm.
English: • Do not use this medicine after the expiry date which is stated on the sachet and the carton after EXP.
Danish: • Brug ikke lægemidlet efter den udløbsdato, der står på brevet og pakningen efter EXP og Udløbsdato.
English: On average, liver iron concentration decreased by 3.80 mg Fe/g dw in patients treated with deferasirox dispersible tablets (starting dose 10 mg/kg/day) and increased by 0.38 mg Fe/g dw in patients treated with placebo (p<0.001).
Danish: I gennemsnit faldt jernkoncentrationen i leveren med 3,80 mg Fe/g tørvægt hos patienter, der blev behandlet med deferasirox dispergible tabletter (startdosis 10 mg/kg/dag), og steg med 0,38 mg Fe/g tørvægt hos patienter, der fik placebo (p<0,001).
English: In patients whose serum ferritin level has reached the target (usually between 500 and 1,000 µg/l), dose reductions in steps of 3.5 to 7 mg/kg should be considered to maintain serum ferritin levels within the target range and to minimise the risk of overchelation.
Danish: Hos patienter, hvis serum-ferritinniveauer har nået målet (som regel mellem 500 og 1.000 µg/l), bør det overvejes at foretage dosisreduktion i trin på 3,5 til 7 mg/kg for at vedligeholde serum-ferritinniveauer inden for det terapeutiske interval, og for at minimere risikoen for overkelering.
English: In a healthy volunteer study, the concomitant administration of deferasirox (single dose of 30 mg/kg, dispersible tablet formulation) and the potent UGT inducer, rifampicin, (repeated dose of 600 mg/day) resulted in a decrease of deferasirox exposure by 44% (90% CI: 37% - 51%).
Danish: Samtidig administration af deferasirox (enkeltdosis på 30 mg/kg, dispergibel tablet-formulering) og den potente UGT-inducer, rifampicin, (gentagen dosis på 600 mg/dag) resulterede i en nedsat eksponering for deferasirox med 44% (90% CI: 37% - 51%) i et studie hos raske frivillige.
English: Uncommon (may affect up to 1 in 100 people)
Danish: Ikke almindelige (kan påvirke op til 1ud af 100 patienter)
English: CARTON OF UNIT PACK
Danish: ÆSKE TIL ENKELTPAKNING
English: • EXJADE 90 mg film-coated tablets are light blue and stamped “90” on one side and “NVR” on the other.
Danish: • EXJADE 90 mg filmovertrukne tabletter er lyseblå og præget med ”90” på den ene side og
English: If only very poor haemosiderosis control is achieved at doses up to 21 mg/kg, a further increase (to a maximum of 28 mg/kg) may not achieve satisfactory control, and alternative treatment options may be considered.
Danish: Hvis der kun er opnået meget dårlig kontrol med hæmosiderosen ved doser på op til 21 mg/kg, er det ikke sikkert, at tilfredsstillende kontrol kan opnås med en yderligere øgning af dosis (til et maksimum på 28 mg/kg), og alternative behandlingsmuligheder bør overvejes.
English: EXJADE 90 mg film-coated tablets EXJADE 180 mg film-coated tablets EXJADE 360 mg film-coated tablets
Danish: EXJADE 90 mg filmovertrukne tabletter EXJADE 180 mg filmovertrukne tabletter EXJADE 360 mg filmovertrukne tabletter
English: <7 ml/kg/month of PRBC (approx. <2 units/month for an adult)
Danish: <7 ml/kg/måned af PRBC (ca. <2 enheder/måne d for en voksen)
English: • Glycosuria in non-diabetics and low levels of serum potassium, phosphate, magnesium or urate, phosphaturia, aminoaciduria (monitor as needed).
Danish: • Glukosuria hos ikke-diabetiske patienter og lave serumkoncentrationer af kalcium, fosfat, magnesium eller urat, fosfaturi, aminoaciduri (monitoreres efter behov) Renal tubulopati er hovedsageligt set hos børn og unge med beta-talassæmi og som blev behandlet med EXJADE.
English: <3 mg Fe/g dw or <300 µg/l
Danish: <3 mg Fe/g tørvægt eller <300 µg/l
English: If only very poor haemosiderosis control is achieved at doses up to 30 mg/kg, a further increase (to a maximum of 40 mg/kg) may not achieve satisfactory control, and alternative treatment options may be considered.
Danish: Hvis der kun er opnået meget dårlig kontrol med hæmosiderosen ved doser på op til 30 mg/kg, er det ikke sikkert, at tilfredsstillende kontrol kan opnås med en yderligere øgning af dosis (til et maksimum på 40 mg/kg), og alternative behandlingsmuligheder bør overvejes.
English: In patients treated with doses greater than 30 mg/kg, dose reductions in steps of 5 to 10 mg/kg should be considered when control has been achieved (e.g. serum ferritin levels persistently below 2,500 µg/l and showing a decreasing trend over time).
Danish: Hos patienter behandlet med doser over 30 mg/kg bør dosisreduktion i trin på 5 til 10 mg/kg overvejes, når der er opnået kontrol (fx serum-ferritinniveauer permanent under 2.500 µg/l og med en faldende tendens over tid).
English: In patients treated with doses greater than 21 mg/kg, dose reductions in steps of 3.5 to 7 mg/kg should be considered when control has been achieved (e.g. serum ferritin levels persistently below 2,500 µg/l and showing a decreasing trend over time).
Danish: Hos patienter behandlet med doser over 21 mg/kg bør dosisreduktion i trin på 3,5 til 7 mg/kg overvejes, når der er opnået kontrol (fx serum-ferritinniveauer permanent under 2.500 µg/l og med en faldende tendens over tid).
English: Excipient with known effect: Each dispersible tablet contains 136 mg lactose.
Danish: Hjælpestof, som behandleren skal være opmærksom på: Hver dispergibel tablet indeholder 136 mg lactose.
English: In case of switching from film-coated tablets/granules to dispersible tablets, the dose of dispersible tablets should be 40% higher than the dose of film-coated tablets/granules, rounded to the nearest whole tablet.
Danish: I tilfælde af behandlingsskift fra filmovertrukne tabletter/granulat til dispergible tabletter, skal dosis for dispergible tabletter være 40% højere end dosis for filmovertrukne tabletter/granulat, afrundet til nærmeste hel tablet.
English: Excipient with known effect: Each dispersible tablet contains 544 mg lactose.
Danish: Hjælpestof, som behandleren skal være opmærksom på: Hver dispergibel tablet indeholder 544 mg lactose.
English: In patients not adequately controlled with doses of 21 mg/kg (e.g. serum ferritin levels persistently above 2,500 µg/l and not showing a decreasing trend over time), doses of up to 28 mg/kg may be considered.
Danish: Hos patienter, der ikke er tilstrækkeligt kontrolleret ved doser på 21 mg/kg (fx serum-ferritinniveauer vedvarende over 2.500 µg/l uden at vise en aftagende udvikling over tid), bør doser op til 28 mg/kg overvejes.
English: During clinical studies, increases in serum creatinine of >33% on ≥2 consecutive occasions, sometimes above the upper limit of the normal range, occurred in about 36% of patients.
Danish: Forhøjelserne var på > 33% i ≥ 2 på hinanden følgende tilfælde, og nogle gange over den øvre grænse af normalområdet.
English: In patients not adequately controlled with doses of 30 mg/kg (e.g. serum ferritin levels persistently above 2,500 µg/l and not showing a decreasing trend over time), doses of up to 40 mg/kg may be considered.
Danish: Hos patienter, der ikke er tilstrækkeligt kontrolleret ved doser på 30 mg/kg (fx serum-ferritinniveauer vedvarende over 2.500 µg/l uden at vise en aftagende udvikling over tid), bør doser op til 40 mg/kg overvejes.
English: • If you experience a combination of drowsiness, upper right abdominal pain, yellowing or increased yellowing of your skin or eyes and dark urine (signs of liver problems),
Danish: • Hvis du oplever en kombination af døsighed, smerter i den øvre højre del af maven, gulfarvning af din hud eller øjne og mørk urin (tegn på leverproblemer)
English: • Do not throw away any medicines via wastewater or household waste.
Danish: Af hensyn til miljøet må du ikke smide medicinrester i afløbet eller, toilettet eller skraldespanden.
English: Excipient with known effect: Each dispersible tablet contains 272 mg lactose.
Danish: Hjælpestof, som behandleren skal være opmærksom på: Hver dispergibel tablet indeholder 272 mg lactose.
English: After every 3 to 6 months of treatment, a dose increase in increments of 5 to 10 mg/kg should be considered if the patient's LIC is ≥7 mg Fe/g dw, or if serum ferritin is consistently >2,000 µg/l and not showing a downward trend, and the patient is tolerating the medicinal product well.
Danish: Hver 3 til 6 måned bør det overvejes at øge dosis med 5-10 mg/kg, hvis patientens LIC er ≥ 7 mg Fe/g tørvægt, eller hvis serumferritin konsekvent er > 2.000 µg/l og ikke viser en nedadgående tendens, og hvis lægemidlet er veltolereret.
English: Starting dose
Danish: Nedsat dosis
English: After every 3 to 6 months of treatment, a dose increase in increments of 3.5 to 7 mg/kg should be considered if the patient's LIC is ≥7 mg Fe/g dw, or if serum ferritin is consistently >2,000 µg/l and not showing a downward trend, and the patient is tolerating the medicinal product well.
Danish: Hver 3 til 6 måned bør det overvejes at øge dosis med 3,5-7 mg/kg, hvis patientens LIC er ≥ 7 mg Fe/g tørvægt, eller hvis serumferritin konsekvent er > 2.000 µg/l og ikke viser en nedadgående tendens, og hvis lægemidlet er veltolereret.
English: OUTER CARTON OF MULTIPACK (INCLUDING BLUE BOX)
Danish: YDRE ÆSKE TIL MULTIPAKNING (inklusive blå boks)
English: EXJADE film-coated tablets demonstrate higher bioavailability compared to the EXJADE dispersible tablet formulation.
Danish: EXJADE filmovertrukne tabletter udviser højere biotilgængelighed sammenlignet med EXJADE dispergible tabletter.
English: Approximate tablet dimensions 10.7 mm x 4.2 mm.
Danish: Omtrentlige tabletdimensioner 10,7 mm x 4,2 mm.
English: Tests of genotoxicity in vitro were negative (Ames test, chromosomal aberration test) while deferasirox caused formation of micronuclei in vivo in the bone marrow, but not liver, of non-iron-loaded rats at lethal doses.
Danish: Ved dødelige doser i ikke-jernophobede rotter forårsagede deferasirox dannelse af mikronuclei in vivo i knoglemarven, men ikke i leveren.
English: Approximate tablet dimensions 20 mm x 5.6 mm.
Danish: Omtrentlige tabletdimensioner 20 mm x 5,6 mm.
English: Hypersensitivity reactions (including anaphylactic reactions and angioedema) Metabolism and nutrition disorders Not known:
Danish: Allergiske reaktioner (inklusive anafylaktiske reaktioner og angioødem)
English: In case of switching from dispersible tablets to film-coated tablets, the dose of the film-coated tablets should be 30% lower than the dose of the dispersible tablets, rounded to the nearest whole tablet.
Danish: I tilfælde af behandlingsskift fra dispergible tabletter til filmovertrukne tabletter, skal dosis for filmovertrukne tabletter være 30% lavere end dosis for dispergible tabletter, afrundet til nærmeste hel tablet.
English: Approximate tablet dimensions 12 mm x 3.6 mm.
Danish: Omtrentlige tabletdimensioner 12 mm x 3,6 mm.
English: ≥7 mg Fe/g dw or >2,000 µg/l
Danish: ≥7 mg Fe/g tørvægt eller >2.000 µg/l
English: EXJADE 360 mg film-coated tablets
Danish: EXJADE 360 mg filmovertrukne tabletter
English: EXJADE 125 mg dispersible tablets Packs containing 28, 84 or 252 dispersible tablets.
Danish: EXJADE 125 mg dispergible tabletter Pakningerne indeholder 28, 84 eller 252 dispergible tabletter.
English: Starting dose The recommended initial daily dose of EXJADE dispersible tablets is 20 mg/kg body weight.
Danish: Startdosis Anbefalet startdosis for EXJADE dispergible tabletter er 20 mg/kg kropsvægt.
English: Interventional post-authorisation safety study (PASS): In order to assess the safety of deferasirox film-coated tablets in the paediatric population (especially when the tablets are crushed), the MAH shall conduct and submit the results of a safety study conducted according to an agreed protocol.
Danish: Non-intervention post-authorisation safety study (PASS): Indehaveren af markedsføringstilladelsen skal udføre og indsende resultater af et sikkerhedsstudie gennemført i henhold til en protokol accepteret af CHMP, for at vurdere sikkerheden af deferasirox filmovertrukne tabletter i den pædiatriske population (særligt, når tabletterne knuses)
English: EXJADE 250 mg dispersible tablets Packs containing 28, 84 or 252 dispersible tablets.
Danish: EXJADE 250 mg dispergible tabletter Pakningerne indeholder 28, 84 eller 252 dispergible tabletter.
English: EXJADE 180 mg film-coated tablets
Danish: EXJADE 180 mg filmovertrukne tabletter
English: 3.5 - 7 mg/kg/day 5-10 mg/kg/day
Danish: 3,5 - 7 mg/kg/dag 5-10 mg/kg/dag
English: The multipacks contain 300 (10 packs of 30) film-coated tablets.
Danish: Multipakningen indeholder 30 (10 pakninger med 30) filmovertrukne tabletter.
English: EXJADE contains lactose
Danish: EXJADE indeholder lactose
English: EXJADE 90 mg film-coated tablets EXJADE 180 mg film-coated tablets EXJADE 360 mg film-coated tablets Deferasirox
Danish: EXJADE 90 mg filmovertrukne tabletter EXJADE 180 mg filmovertrukne tabletter EXJADE 360 mg filmovertrukne tabletter Deferasirox
English: 14 mg/kg/day 20 mg/kg/day
Danish: 14 mg/kg/dag 20 mg/kg/dag
English: How to take EXJADE
Danish: Sådan skal du tage EXJADE